Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor

Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor

US Patent 11413282 · Granted Aug 16, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods of treating cancer by administering tumor necrosis factor (TNF) family l2025
Use of a cathepsin s inhibitor against the formation of anti-drug antibodies2025
Bispecific antibodies specific for PD1 and TIM32025
Bispecific anti-human A-beta/anti-human transferrin receptor antibodies2025
Methods to determine antibody activity in tumor samples2025
Trispecific antibodies specific for HER2 and a blood brain barrier receptor and 2025
Antigen binding receptors specific for mutated Fc domains2025
Anti-FAP antibodies and methods of use2025
Combination therapy with targeted 4-1BB (CD137) agonists2025
Bispecific antigen binding molecules comprising anti-FAP clone 2122025
Bispecific antibodies specific for OX402025
Bispecific 2+1 contorsbodies2025